tPBM for Autism
Trial Summary
What is the purpose of this trial?
This trial is testing a new light-based treatment called tPBM for adults with Autism Spectrum Disorder (ASD). The treatment aims to improve brain function by increasing energy production in brain cells. The study will evaluate if this treatment is safe and effective for reducing ASD symptoms.
Will I have to stop taking my current medications?
The trial requires that if you are taking psychotropic medications, your dose must be stable for at least 4 weeks before starting the study. If your medication dose is not stable, you may need to adjust it before participating.
What data supports the effectiveness of the treatment tPBM for Autism?
Research shows that transcranial photobiomodulation (tPBM) can reduce autism symptoms, such as social communication difficulties and repetitive behaviors, in both adults and children with autism spectrum disorder (ASD). Studies also suggest that tPBM may improve overall functioning and quality of life in individuals with ASD.12345
Is transcranial photobiomodulation (tPBM) safe for humans?
Research indicates that transcranial photobiomodulation (tPBM) is generally safe for humans, with only mild side effects like insomnia, headache, and warmth at the treatment site reported in some cases. No serious adverse events have been noted, and no changes in treatment protocols were required due to side effects.23467
How does transcranial photobiomodulation (tPBM) treatment for autism differ from other treatments?
Transcranial photobiomodulation (tPBM) is a unique treatment for autism because it uses light to stimulate brain activity, which is different from traditional drug therapies. It is non-invasive and focuses on improving social and communication skills by targeting neural tissues, offering a novel approach where no standard pharmacological treatments exist for core autism features.23489
Research Team
T. Atilla Ceranoglu, MD
Principal Investigator
Massachusetts General Hospital
Eligibility Criteria
Adults aged 18-59 with Autism Spectrum Disorder (ASD) who can understand the study and give informed consent are eligible. They should not have intellectual disabilities, unstable psychiatric conditions, or serious safety risks. Women must use double-barrier contraception if applicable.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive transcranial photobiomodulation (tPBM) or sham treatment for 8 weeks to assess efficacy, safety, and tolerability in ASD
Follow-up
Participants are monitored for safety and effectiveness after treatment
Treatment Details
Interventions
- Placebo/ Sham
- Transcranial Photobiomodulation (tPBM)
Find a Clinic Near You
Who Is Running the Clinical Trial?
Massachusetts General Hospital
Lead Sponsor